Illumina (ILMN) and EraGen to Form Strategic Partnership

November 18, 2009 10:22 AM EST

EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc. (NASDAQ: ILMN) today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.

Under these licensing agreements, EraGen Biosciences will have access to Illumina's BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen's MultiCode-PLx technology for the life sciences, research and clinical markets.


Related Categories

Corporate News

Stocks Mentioned

ILMN 35.83

+0.00 +0.00%
Volume: 1,638,909
Track ILMN


Add Your Comment





Follow StreetInsider.com On Twitter